Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Findings from Ohio State University provide new insights into breast cancer
April 7th, 2009
"The Survivor's Health and Reaction (SHARE) study examined health-related quality of life (HRQL) in breast cancer patients who had participated in Cancer and Leukemia Group B Trial 8541 from 1985 to 1991. In total, 245 survivors (78% of eligible patients) who were 9.4 to 16.5 years post-diagnosis (mean, 12.5 years postdiagnosis) completed HRQL surveys relating to 5 domains," scientists writing in the journal Cancer report. "Analyses examined HRQL domains according to 3 different chemotherapy dose levels that were administered in the original treatment trial: low-dose cyclophosphamide, doxorubicin, and fluorouracil (CAF) at 300 mg/m(2), 30 mg/m(2), and 300 x 2...
Source: Cancer Weekly (2009-04-07)
|
